Published in Vaccine Weekly, November 8th, 1999
The randomized, double-blind, placebo-controlled trial included 94 children between the ages of five and 18 with new-onset type 1 diabetes. The children received either BCG or saline administered intradermally within four months of experiencing symptoms. They were followed-up every three months for two years.
"The primary end point was remission, defined as insulin independence for four weeks. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.